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ABSTRACT Alpaca-derived single-domain antibody fragments (VHHs) that target the influenza A virus nucleoprotein (NP) can
protect cells from infection when expressed in the cytosol. We found that one such VHH, NP-VHH1, exhibits antiviral activity
similar to that of Mx proteins by blocking nuclear import of incoming viral ribonucleoproteins (vRNPs) and viral transcription
and replication in the nucleus. We determined a 3.2-Å crystal structure of NP-VHH1 in complex with influenza A virus NP.
The VHH binds to a nonconserved region on the body domain of NP, which has been associated with binding to host factors and
serves as a determinant of host range. Several of the NP/VHH interface residues determine sensitivity of NP to antiviral Mx
GTPases. The structure of the NP/NP-VHH1 complex affords a plausible explanation for the inhibitory properties of the VHH
and suggests a rationale for the antiviral properties of Mx proteins. Such knowledge can be leveraged for much-needed novel
antiviral strategies.
IMPORTANCE Influenza virus strains can rapidly escape from protection afforded by seasonal vaccines or acquire resistance to
available drugs. Additional ways to interfere with the virus life cycle are therefore urgently needed. The influenza virus nucleo-
protein is one promising target for antiviral interventions. We have previously isolated alpaca-derived single-domain antibody
fragments (VHHs) that protect cells from influenza virus infection if expressed intracellularly. We show here that one such VHH
exhibits antiviral activities similar to those of proteins of the cellular antiviral defense (Mx proteins). We determined the three-
dimensional structure of this VHH in complex with the influenza virus nucleoprotein and identified the interaction site, which
overlaps regions that determine sensitivity of the virus to Mx proteins. Our data define a new vulnerability of influenza virus,
help us to better understand the cellular antiviral mechanisms, and provide a well-characterized tool to further study them.
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Seasonal human influenza A virus (IAV) epidemics and occa-sional pandemics cause significant morbidity and continue to
pose a large economic burden. Influenza A virus is a segmented,
negative-stranded RNA virus and belongs to the family Ortho-
myxoviridae. To infect a cell, virus particlesmust fusewith the host
cell membrane to release the viral ribonucleoprotein (vRNP)
complexes into the cytosol. vRNPs must then cross the nuclear
membrane to enter the nucleus, where viral transcription and rep-
lication take place.
vRNPs contain a negative-stranded RNA genome segment
decorated by many copies of the nucleoprotein (NP). NP bound
to viral RNA (vRNA) assembles into two helical, antiparallel
strands that form a loop at one end. At the other end, the hetero-
trimeric polymerase, comprised of PA, PB1, and PB2, is posi-
tioned and binds to the base-paired, conserved ends of the vRNA
as well as to NP.
The major vRNP component, NP, is a basic, ~56-kDa protein
consisting of a head and body domain and a tail loop (amino acids
[aa] 402 to 428). In the context of a vRNP, the tail loop protrudes
into adjacent NP molecules and mediates oligomerization (1).
Besides binding and condensing vRNA, the diverse functions
of NP include nuclear import, export, and RNA synthesis. NP
interacts with the viral proteins M1 and PB2 and a variety of
host proteins (2–6). Because of its complex interactions, NP is
a key determinant of host specificity, such that IAV strains with
NP sequences of avian origin are much less virulent in human
cells (7, 8).
Nuclear import of vRNPs throughnuclear pores ismediated by
importin-/. At least two nuclear localization sequences (NLSs)
that are recognized by the different importin- isoforms are pres-
ent on NP, including a nonconventional NLS (NLS1, NP residues
3 to 13) and NLS2, comprising residues 198 to 216 (9, 10). NP is
dispensable for transcription of short (100 nucleotides [nt])
vRNA-like templates but is essential for transcription and replica-
tion of full-length viral genome segments. NP thus serves as a
crucial factor for transcript elongation (11). Newly synthesized
NP exists as monomers and small oligomers (trimers) and is im-
ported into the nucleus to assemble new vRNPs (12). Later in
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infection, the progeny vRNPs are exported to the cytosol with the
aid of the viral nuclear export protein (NEP), M1, and the host
CRM1 export machinery for delivery to the budding site (5, 13).
Anti-influenza virus drugs and vaccines have traditionally tar-
geted the surface-exposed viral hemagglutinin (HA), neuramini-
dase (NA), or the ion channel M2. The selective pressure exerted
by drugs, antibodies, and T cells confers a selective advantage on
those viruses with mutations in their surface proteins as a means
of escape (antigenic drift). Strain-dependent sequence variation
in other influenza virus proteins, such as NP, exists but is far
less prominent than the antigenic drift seen for HA, NA, and
M2 variants.
Alternative approaches to traditional interventions must
therefore target the more conserved proteins of the viral RNP
complex to prevent them from entering the nucleus or to inhibit
the associated activity of the RNA-dependent RNA polymerase, a
vulnerability of the virus that is also exploited by host antiviralMx
proteins. Mx GTPases are interferon-induced effectors of the cell-
autonomous antiviral immune response, with broad specificity
against a number of RNA viruses. Although molecular details of
howMx proteins exert their antiviral activity are unknown, we do
know the stages in the viral life cycle that are perturbed by Mx
proteins (14). The human MxA protein is localized in the cytosol
and prevents nuclear import of incoming vRNPs (15). In contrast,
mouse Mx1, a close homolog, is localized in the nucleus and in-
terferes with viral transcription and replication (14).
To better relate specific contributions of different NP surface
regions to their function and to identify new vulnerabilities that
perturb the viral life cycle, we have used intracellularly expressed
variable domains of alpaca heavy-chain-only antibodies (VHHs)
that target IAVNP. In contrast to conventional antibodies or their
fragments, camelid heavy-chain-only antibodies recognize their
target with a single variable binding domain. As fragments, these
~15-kDa antibody domains can bind with high affinity and spec-
ificity and are soluble and mostly independent of stabilization by
disulfide bonds. This allows expression of VHHs in the cytosol of
mammalian cells with retention of their binding properties. Intra-
cellular expression of the anti-NP VHHs during IAV infection
disrupts the viral replication cycle at an early stage by preventing
essential nuclear import of incoming vRNPs but not of NP alone
(16, 17). We can thus target a specific NP surface and examine the
consequences for virus replication.
We found that one of our NP-specific VHHs, NP-VHH1,
blocks vRNP nuclear import, viral transcription, and replication
in a similar fashion as do interferon-induced, antiviral Mx pro-
teins. We used VHHs as crystallization chaperones to grow crys-
tals of recombinant NP in complex with NP-VHH1. The 3.2-Å
crystal structure reveals that the VHH binding site overlaps a re-
gion associated with viral sensitivity to Mx proteins. According to
one of the proposed vRNP structures, VHH binding occludes ac-
cess to NLS2 on the adjacent NPmolecule, thus providing a plau-
sible mechanistic explanation for the antiviral activity of NP-
VHH1 and Mx proteins.
RESULTS
NP-VHH1 inhibits virus replication after nuclear import of
vRNPs.We reported elsewhere the identification of several VHHs
that target influenza virus NP (16, 17). When expressed in the
cytosol, almost all identified VHHs block nuclear import of in-
coming vRNPs. Due to the multiple roles of NP in the viral life
cycle, it is likely that VHHs interfere with virus replication at mul-
tiple steps. We tested the effect of NP-VHH1 in the course of an
influenza virus infection in A549 cell derivatives in which VHH
expression is doxycycline inducible. Since NP-VHH1 inhibits
the initial nuclear import of vRNPs, we infected cells with influ-
enza virus and induced expression ofNP-VHH1 in the cytosol at
different time points from 16 h before to 5 h after infection. We
expected that induction of VHH expression after infection would
permit vRNP import into the nucleus, which would then allow us
to examine the effects of NP-VHH1 after this step. We assessed
expression levels of NP and HA-tagged anti-NP-VHH1 by flow
cytometry 6 h postinfection (p.i.), using anti-NP-VHH2 Alexa
Fluor (AF) 647 (another NP-specific VHH) and an Alexa Fluor
488-labeledmonoclonal anti-HA antibody, respectively (Fig. 1A).
VHH levels were lower when their expression was induced at later
time points, while the fraction of NP-positive cells and thus infec-
tion was higher. When expression was induced 3 or 4 h p.i., VHH
levels were barely detectable, which we attribute to influenza
virus-mediated shutdown of host protein synthesis (18). Induc-
tion of VHH expression as early as 1 h prior to infection was
sufficient to prevent most de novoNP production, likely by limit-
ing access of vRNPs to the nucleus. A substantial fraction of cells
still expressed NP when doxycycline was added simultaneously
with infection or 2 h p.i. This leaves a narrow window to allow
VHH expression in infected cells to study VHHperturbation after
nuclear import. To evaluate the effect of the small quantities of
VHH induced at 0 and 2 h p.i., we used the same experimental
setup as before but instead quantified virus titers in the superna-
tants (Fig. 1B). Time points that allowed both VHH production
and NP synthesis (0 and 2 h p.i.) yielded drastically reduced virus
titers. This suggests that NP-VHH1 impairs viral replication in
ways other than its interference with nuclear import of incoming
vRNPs.
NP-VHH1 inhibits replication/transcription of long RNA
segments. Nuclear import of vRNPs is followed by transcription
and replication of viral genome segments. We have previously
analyzed polymerase activity in the presence of NP-specific VHHs
using a transfection-based polymerase reconstitution assay in
293T cells, bypassing natural infection and nuclear import of
vRNPs.We found thatNP-VHH1 fused tomCherry blocked the
synthesis of the template genome encoding the viral NA (16), but
HA-taggedNP-VHH1 did not affect transcription of an artificial
genome segment encoding enhanced green fluorescent protein
(EGFP) in independent experiments (17). We excluded the pos-
sibility that the size of the VHH fusions contributed to this dis-
crepancy (data not shown). Since the template genome segments
that we used differ in their length, we speculated that the VHH
may interfere with the role of NP in transcript elongation. An
interference with elongation that is dependent on the length of the
viral genome segment is also seen for antiviralMx proteins located
in the nucleus (14). Initiation and synthesis of primary viral tran-
scripts forM1 andNS2 are barely affected byMx1, butMx1 inter-
feres with the synthesis of the longer transcripts encodingNP,HA,
PA, PB2, or PB1 (14). To test whether the inhibitory effect of
NP-VHH1 during transcription and replication is dependent on
the length of the transcript, we designed two artificial genome
segments: one encodingEGFPon a 720-nucleotide (nt) transcript,
the other encoding mCherry-T2A-EGFP on a 1,500-nt transcript.
This approach enabled us to compare templates of different
lengths in a polymerase reconstitution assay, while measuring
Hanke et al.
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the same fluorescent molecule as a readout (EGFP). We
cotransfected a control VHH (VHH7, anti-murine major his-
tocompatibility complex class II [MHCII]), NP-VHH1, hu-
man MxA, or murine Mx1 and quantified EGFP-positive cells
24 h posttransfection (Fig. 2). The fraction of EGFP-positive
cells in the presence of all tested proteins was unaffected for the
short 720-nt template, at least at the cotransfected amounts of
plasmid DNA. The 1,500-nt genome segment showed reduced
overall expression compared to the 720-nt genome segment in
the absence of any perturbants. Cotransfection of Mx1 or NP-
VHH1 clearly reduced EGFP-positive cells and thus polymer-
ase efficiency on the 1,500-nt transcript, while the control
VHH and MxA did not affect EGFP expression. We thus show
that, similarly to Mx proteins in the nucleus, NP-VHH1 in-
teracts with NP in a manner that does not block initiation of
polymerase activity but rather hinders NP in its role as a factor
for transcript elongation by the RNA-dependent polymerase.
This also explains the reduced virus titers in the presence of
anti-NP-VHH1, although we cannot exclude the possibility
that additional stages of the replication cycle, such as nuclear
export, transport to the budding site, and virion assembly, are
impaired by the VHH as well.
FIG 1 NP-VHH1 impairs influenza A virus replication at early and late time points. A549 cells expressing NP-VHH1-HA in a doxycycline (Dox)-inducible
manner were seeded 24 h before influenza A virus (IAV) infection. VHH expression was induced at the indicated time points relative to infection; cells were
infected with IAV at anMOI of 1 at t 0 h. (A) Cells were harvested 6 h postinfection (p.i.), stained for HA and NP, and analyzed by flow cytometry. Geometric
mean of anti-HA-Alexa Fluor 488 (VHH expression level, red) and fraction of infected cells (NP positive, gray) are shown. Mean values standard deviations
from technical duplicates are displayed. (B) Supernatants were collected 24 h p.i., and titers were determined on MDCK cells. Twenty-four hours p.i., NP in
infected MDCK cells (nuclei) was stained with NP-VHH2-TAMRA, and infected cells were quantified by CellProfiler. Data from three independent experi-
ments ( standard errors of the means) are shown.
FIG 2 Inhibition of polymerase activity by NP-VHH1 and Mx1 is dependent on transcript length. 293T cells were transfected with expression vectors for
influenza virus A/WSN/33 PA, PB1, PB2, and NP, as well as the indicated VHHs or Mx proteins. In addition, we cotransfected plasmid pPolI-RT, from which a
synthetic genome segment was transcribed which encoded either EGFP (720 nt) or mCherry-T2A-EGFP (1,500 nt). Twenty-four hours posttransfection,
EGFP-positive cells were quantified by flow cytometry. Since reduced EGFP levels were expressed from the mCherry-T2A-EGFP construct, values were
normalized to EGFP-positive cells expressing VHH7 (control). Data from three independent experiments are shown ( standard errors of themeans). Statistical
significance was assessed by Student’s t test (**, P 0.01; ns, not significant).
Structure of Inﬂuenza Virus NP with Antiviral VHH
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NP-VHH1binds to theNPbody domain.To define themo-
lecular binding site of NP-VHH1 on NP as a means of obtaining
mechanistic insight into its inhibitory properties, we determined
the binding site by X-ray crystallography. To produce the NP/
NP-VHH1 complex, we expressed and purified both proteins
individually. We then combined the proteins in a 1:3 NP/NP-
VHH1 molar ratio and purified the complex by size exclusion
chromatography. In the absence of RNA, purified NP exists as
monomers or trimers, and the oligomerization state can be influ-
enced by salt concentration (19). As in vRNPs, the NP-NP inter-
action in trimers is facilitated by the NP tail loop that protrudes
into an adjacent NP molecule (20). In the size exclusion elution
profile, bothmonomeric and trimeric peaks shift after addition of
the VHH, indicating that binding of the VHH does not affect NP
oligomerization and that NP-VHH1 can interact with both spe-
cies (Fig. 3A).
We obtained cocrystals of the complex that diffracted to 3.2 Å
(Table 1) and solved the structure by molecular replacement
(MR) using the available structures of NP (PDB identifier [ID]
2IQH) and a VHH (PDB ID 4KRL) as reference models (1, 21).
Ourmodel was refined to a finalRwork of 20.4% andRfree of 26.1%.
The NP/NP-VHH1 complex resembles previously characterized
NP structures, forming a trimer with the tail loops projecting into
the adjacent NPmolecule (Fig. 3B) (1, 22). Anti-NP-VHH1 binds
to the body domain at the end opposite the tail loop of each NP
monomer (Fig. 3B and C), underlining that it does not interfere
with oligomerization of NP. Despite being a potent inhibitor of
vRNP nuclear import, the VHH binding site is distant from the
known NLS1 and NLS2 (Fig. 3C and D). It is also not in the
proximity of the RNA binding cleft (Fig. 3C) and thus likely does
not alter binding of NP to RNA.
NP-VHH1 binds a variable surface on NP associated with
host adaptation. We identified the residues involved in the NP/
NP-VHH1 binding interface using PDBePISA (23). The VHH
uses residues from all of its three complementary determining
regions (CDRs) to interact with NP. On NP, NP-VHH1 bur-
ies a total of 23 residues and an interface of 542 Å2 (Fig. 4A).
The manner in which the VHH binds NP suggests that it exerts
its antiviral properties due to the steric exclusion of potential
NP binding partners, including viral or host proteins. The NP
binding interface is dispersed over discontinuous elements of
secondary structure, which explains why the VHH binds only
to correctly folded but not to denatured NP, for example in
immunoblotting assays (data not shown). To validate that
NP-VHH1 engages NP at the determined binding site, we
generated an E375R mutant of NP, showed that it is expressed
to wild-type levels, and confirmed that this mutation in the
binding site results in a loss of anti-NP-VHH1 binding (see
Fig. S1 in the supplemental material).
To analyze the possible extent of structural conservation of NP
at theVHHbinding interface, we evaluated conservation grades of
the interface residues acquired by large-scale surveys of NP se-
quences (24). Kukol and Hughes (24) determined conservation
grade scores of NP residues using the ConSurf algorithm, which
takes into account evolutionary relationships between protein se-
quences. None of the interface residues were strictly conserved,
only 17% were considered conserved, 43% were considered vari-
able, and 39% received scores for an average degree of conserva-
tion. Part of the binding interface represents the largest cluster of
variable residues on the otherwise rather conserved NP (Fig. 4D).
Despite binding to a variable region onNP, we confirmed binding
ofNP-VHH1 to the commonly used laboratory strainsWSNand
PR8 (see Fig. S2 in the supplemental material).
Functional properties of NP are often investigated by mu-
tagenesis or by analysis of naturally occurring, adaptive muta-
tions. In agreement with their variable character, several of the 23
interface residues have been examined in the context of interspe-
cies adaptation. These residues include Asn319, which enhances
importin- affinity (Fig. 4C), and residues Tyr52, Asn101,
Tyr313, Glu375, and Ser377, which undergo convergent changes
in the process of adaptation fromavian to humanhosts (8, 25–30).
In agreement with the similarity of viral inhibition between NP-
VHH1 and Mx proteins, the NP-VHH1 binding interface over-
laps with a cluster of residues (Tyr52, Glu53, Val100, Ser283, and
Tyr313) (Fig. 4B)whosemutation allows escape fromMxproteins
(31–33).
Efforts to screen for small-molecule antivirals that perturb the
viral replication cycle have yielded a handful of inhibitors that
target NP (34, 35). One of them, nucleozin, promotes cytosolic
accumulation of incoming vRNPs. Two independent binding sites
have been identified for nucleozin (35). One of the two binding
sites, at residue Tyr52, overlaps the NP-VHH1 binding site
(Fig. 4E). The second nucleozin binding site, Tyr289/Asn309, is in
close proximity to Tyr52 but is not masked by NP-VHH1 and
should therefore be accessible to the drug in the presence of NP-
VHH1. However, the proximity highlights the susceptibility of
this NP surface to interference, and NP-VHH1 may thus also
help in better understanding the inhibitory properties of nu-
cleozin and its derivates.
Effects of NP-VHH1 on vRNP integrity and nuclear im-
port.Neither of the two characterized NLSs is in proximity to the
NP-VHH1 binding site (Fig. 3C and D). Nuclear import of NP
alone is unaffected by NP-VHH1, while nuclear import of in-
coming vRNPs is strongly inhibited (16, 17). Thus, the structure
of the vRNP complex must be important for NP-VHH1 to elicit
its inhibitory function.
To evaluate the general effect of NP-VHH1 binding to
vRNPs, we purified vRNPs from virions, added an excess of NP-
VHH1 or a control VHH, and analyzed the appearance of vRNPs
by negative-stain electron microscopy (EM). We did not detect
gross differences between vRNPs complexed with anti-NP-
VHH1, indicating that NP-VHH1 does not disrupt the overall
structure of the complex (Fig. 5A). A typical VHH is 2 by 3.5 nm in
size (36). Assuming that the VHH binds to the periphery of the
vRNP, one would expect a slight increase of vRNP width. How-
ever, vRNPs examined in the presence of NP-VHH1 exhibit a
slightly reduced width (Fig. 5B). Purified vRNPs often adopted
a slightly curved shape. Upon addition ofNP-VHH1, we noted a
trend for vRNPs to adopt curved shapes less frequently, but we
were unable to validate this tendency statistically.
To analyze the possible impact of NP-VHH1 binding to
vRNPs on a structural level, we examined the two available
cryo-EMmodels of vRNPs (37, 38).While overall similar, the two
models differ in NP orientation and handedness. The binding
interface for NP-VHH1 is exposed in both models and should
thus allow VHH binding. The right-handed helical model of
Moeller et al. is based on vRNPs purified from transiently trans-
fected cells transcribing influenza virus genome segments and ex-
pressing NP and polymerase subunits (38). When we superim-
pose our structure on this model, NP-VHH1 blocks the major
Hanke et al.
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FIG 3 NP-VHH1 binds to the body domain of NP. (A) NP alone (blue) or preincubated with an excess of NP-VHH1 (red) was subjected to size exclusion
chromatography with a Superdex 200 column. Absorbance at 280 nm of the elution profile is displayed (left). Samples of the peak fractions 1, 2, and 3 were
analyzed by SDS-PAGE and Coomassie blue staining (right). (B and C) Ribbon representation of NP-VHH1 in complex with NP. (B) The three assembled NP
molecules that form the trimer are shown in yellow, red, and blue; the VHH (gray) is bound opposite the tail loop. (C) NPmonomer bound by NP-VHH1. NP
subdomains, RNA binding cleft, and NLS2 are indicated. NLS1 is disordered in the electron density maps and not shown. All illustrations were generated in
PyMOL. (D) Sequence of influenza virus A/WSN/33 NP. The NP/NP-VHH1 interface residues are shown in green. “H” labels residues involved in hydrogen
(Continued)
Structure of Inﬂuenza Virus NP with Antiviral VHH
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groove of the vRNP complex (Fig. 5C), which would reduce the
accessible surface of the vRNP and thus limit interactions of the
vRNP with other viral and host proteins.
The vRNPs that were used for the left-handed helical model of
Arranz et al. (37) derive from purified virions and therefore more
likely represent the incoming vRNPs encountered by anti-NP-
VHH1 in the cytosol. Modeled onto this structure, anti-NP-
VHH1 is positioned on the edge of the major groove without
blocking it (Fig. 5D). Instead,NP-VHH1 slightly clasheswith the
head domain of the adjoining NP molecule. Considering the in-
herent structural flexibility of the NP tail loop and thus of vRNPs,
this clash may not be all that detrimental. However, the necessary
structural compensationmight explain the slightly thinner vRNPs
observed by EM and why some vRNPs appear less curved. Impor-
tantly, according to this model, NP-VHH1 masks NLS2 of the
adjacent NP protomer, providing a plausible explanation for the
inhibition of vRNP nuclear import.
DISCUSSION
To identify new vulnerabilities in the life cycle of influenzaA virus,
we used cytosolically expressed single-domain antibodies, also
called VHHs, that target the nucleoprotein (NP). To relate the
inhibitory properties ofNP-VHH1 to the structural features that
it recognizes on NP, we determined the crystal structure of the
VHH in complex with NP. The binding site of NP-VHH1 over-
laps evolutionarily variable residues implicated in interactions
Figure Legend Continued
bonds, and “S” labels residues engaged in the salt bridge at the NP-VHH1 interface. Conserved interface residues are marked with a “C” (conservation grades
8 to 9), and variable interface residues are marked with a “V” (conservation grades 1 to 3) according to the work of Kukol and Hughes (24). Unlabeled interface
residues exhibit average conservation grades. The two nuclear localization sequences (NLSs) of NP are shown in purple and magenta. Residues associated with
sensitivity of influenza A virus to Mx proteins are indicated with an “M” (31–33); residues enhancing importin- binding are indicated with “” (25).
TABLE 1 Data collection and refinement statistics
Characteristic Influenza A virus NP, NP-VHH1 native
Protein
Organism Influenza A virus, Vicugna pacos
PDB ID 5TJW
Data collection
Space group P213
a, b, c (Å) 137.548, 137.548, 137.548
, ,  (°) 90.0, 90.0, 90.0
Wavelength (Å) 0.9778
Resolution range (Å) 97.26–3.22 (3.34–3.22)a
No. of total reflections 132,024
No. of unique reflections 14,205
Completeness (%) 99.9 (100.0)
Redundancy 9.3 (7.9)
Rsym (%) 17.8 (100.0)
Rp.i.m. (%) 6.6 (44.2)
I/ 15.4 (2.1)
CC1/2 (%) 99.6 (68.7)
Refinement
Resolution range (Å) 97.26–3.23
Rwork (%) 20.44
Rfree (%) 26.16
Coordinate error (Å) 0.38
No. of reflections
Total 14,189
Rfree reflections 1,419
No. of nonhydrogen atoms 4,579
No. of protein atoms 4,579
Root mean square deviations
Bond lengths (Å) 0.005
Bond angles (°) 0.63
Avg B factors (Å2)
Protein 74.65
Ramachandran (%)
Favored (%) 96.4
Allowed (%) 3.43
Outlier (%) 0.17
Clash score 9.53
MolProbity score 1.74
MolProbity percentile 100th
a Values in parentheses are for highest-resolution shell.
Hanke et al.
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with host proteins, including both a supporting (importin-) and
an antagonizing (Mx proteins) host factor. NP-VHH1 exploits a
surprisingly similar vulnerability as do the host’s antiviral,
interferon-induced Mx proteins.
The antiviral activity ofMxGTPases has long been recognized,
first described as a restriction factor for influenza A virus (39).
While there is consensus on the general antiviral activity of MxA/
Mx1 as an entity that targets both the viral PB2 and NP, the exact
mode of action has remained elusive. Several residues on NP alter
viral susceptibility to Mx1 proteins, some of which are occluded
by NP-VHH1. Whether these residues directly alter affinity to
Mx proteins has so far not been shown, and no structure of anMx
protein in complex with NP has been reported. Because of possi-
ble alternative binding sites and affinities ofMx tomonomeric NP
versus NP assembled in vRNPs, these interactions might be diffi-
cult to show unambiguously. Our data show that occluding this
surface on the NP body domain is sufficient tomimic the antiviral
activity of Mx GTPases, suggesting that a direct interaction of Mx
proteins with this surface is likely. The involvement of (an) addi-
tional, unknown factor(s) that contribute(s) toMx activity cannot
be excluded. However, we can conclude that targeting NP alone,
and not PB2, is sufficient to mimic the effect of Mx proteins.
Because of the structurally defined NP-VHH1 binding site on
NP, it is the ideal model protein to investigate possible antiviral
mechanisms of Mx proteins.
Antiviral effects of Mx are dependent on GTPase activity in
most settings (40).Mx proteins are known to form ring-like struc-
tures that—in the case of MxA—are thought to clasp around the
incoming vRNPs to prevent nuclear import (41). Our VHHs lack
any enzymatic activity and do not oligomerize, suggesting that
high-affinity binding may be sufficient for antiviral activity. Oli-
gomerization and the resulting avidity effects may allow the same
antiviral mechanism at lower-affinity interactions between NP
and Mx proteins. In the light of evolution, this may be advanta-
geous for two reasons: (i) it allows a single Mx homolog to act as a
potent broad-spectrum effector that binds to multiple virus fam-
ilies with lower affinity and (ii) if low-affinity binding is sufficient
for antiviral activity, then it would bemore difficult to escape from
all Mx activity by antigenic drift.
Superposition of NP-VHH1 on EM-based vRNP models
showed that NP-VHH1 could mask the NLS2 on adjoining
NP molecules. Mx proteins might function in a similar fashion
and prevent vRNP interactions with host factors, including
those important for nuclear import. Indeed, a crucial residue
for host specificity that enhances binding to importin-,
Asn319, is found in the interface with NP-VHH1. In addition,
escape from Mx proteins with mutations in residues Val100,
Ser283, and Tyr313 occurs at the expense of nuclear import
efficiency (32).
Why this surface is important for nuclear import of vRNPs is
unknown. Modeled on the vRNP structure from the work of Ar-
ranz et al. (37), our data showed the proximity of NP-VHH1 to
the NLS2 on an adjoining NP molecule, suggesting that VHH
binding to vRNPs prevents importin binding to NLS2. It is con-
ceivable that importin-, when bound specifically to one NLS of
NP, is stabilized by residues of the NP-VHH1 interface, includ-
ing Val100, Ser283, Tyr313, and Tyr319. However, the inherent
flexibility and heterogeneity of the vRNP complexes present ama-
FIG 4 Binding interface of NP and NP-VHH1. Surface representation of an NPmonomer withmagnified view of the NP/NP-VHH1 interface. (A) Residues
involved in the interaction that are at least partially occluded uponVHHbinding are shown in green. (B) Residues associated with sensitivity of influenza A virus
to Mx proteins are shown in blue. (C) The residue that enhances binding to importin- is shown in purple. (D) Variable interface residues that are part of the
largest cluster of variable residues of NP according to the work of Kukol and Hughes (24) are shown in red. (E) The two independent nucleozin binding sites are
displayed in orange (34, 50).
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jor challenge to prove this contention by structural means.
Higher-resolution structures of the vRNP complex, ideally com-
plexed with host factors, are needed. The structure of anti-NP-
VHH1 with NP might be of use in determining the exact orienta-
tion of NP and handedness of the helix in such higher-order
complexes by yielding more static templates for analysis.
The strength of intracellular VHHs as specific perturbants of
protein function is their ability to mask specific structurally de-
finedNP epitopes without priormanipulation of the virus bymu-
tation. This approach is inherently limited by the ability of the
virus to shut down host protein synthesis, including that of inhib-
itory VHHs. While we were able to circumvent these limitations
using inducible VHH expression to some extent, cell-penetrating
VHHs or other means of permeabilization that allow efficient de-
livery from extracellular space could also find application (42, 43).
Such an approach would allow an evaluation of the importance of
the blocked surface at later stages of infection and, importantly,
transform VHHs into discovery tools for antiviral agents suitable
for therapeutic intervention.
Given the continued relevance of influenza virus as a serious
health threat and its ability to rapidly acquire resistance against
drugs or escape from immune responses that target HA, NA, and
M2, the more conserved influenza virus proteins, including NP,
may prove to be alternative targets for intervention. So far, we
have developed more than 20 IAVNP-specific VHHs that bind to
at least four unique binding sites on NP (16, 17). Continued ef-
forts in this direction might help to map more precisely the con-
tributions of different NP surfaces to the influenza virus life cycle
and inspire the development of novel antivirals. In conclusion, the
crystal structure of an inhibitory VHH in complex with NP un-
covers a new vulnerability in the virus life cycle and may pheno-
copy mechanisms of actions of the cellular antiviral defense. The
ease of expression and the capability of binding to common
laboratory-adapted influenza virus strains, combinedwith our de-
tailed molecular characterization of the binding site, make NP-
VHH1 a versatile tool to identify the specific contributions of this
NP surface and of host factors that potentially compete withNP-
VHH1 for binding.
FIG 5 NP-VHH1 binding to vRNPs. (A) vRNPs purified from influenza virus A/PR/8/34 virions were treated with an excess of NP-VHH1 or a control VHH
(VHHHA68 against IAVHA [51]) and visualized by negative-stain electronmicroscopy. (B) The width of vRNPs (n 28) was measured at two positions using
ImageJ. A two-tailed Student t test was performed to evaluate statistical significance. (C andD) Superposition of the NP/NP-VHH1 structure on vRNPmodels
from thework ofMoeller et al. (38) (PDB ID2YMN) (C) andArranz et al. (37) (PDB ID4BBL) (D). Electron density is shown for bothmodels, and coloredVHHs
are located according to the NP orientation in the model.
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MATERIALS AND METHODS
Virus. Influenza A/WSN/33 virus used for infection experiments was
propagated and titrated on MDCK cells. Infections were performed in
Dulbecco modified Eagle medium (DMEM) with 0.3% bovine serum
albumin (BSA) for 1 h at 37°C. vRNPs were purified from influenza virus
A/PR/8/34 virions purchased from Charles River Laboratories.
Cell lines.HumanHEK293T cells and dogMDCKcells were obtained
from ATCC and grown in DMEM with 10% fetal bovine serum (FBS).
The A549 cell line inducibly expressing NP-VHH1-HA, derived from
A549 cells obtained from ATCC, was described earlier (16) and was cul-
tivated in DMEM with 10% FBS and 500 g/ml G418.
Reagents. Doxycycline hyclate (Dox) was purchased from Sigma-
Aldrich. Nickel-nitrilotriacetic acid (NTA) beads were purchased from
Qiagen. Mouse anti-HA.11 (clone 16B12) coupled to Alexa Fluor (AF)
488 was purchased from Life Technologies. Mouse anti-HA.11 (clone
16B12) was acquired from BioLegend. VHHs coupled to either Alexa
Fluor (AF) 647 or 5-carboxytetramethylrhodamine (TAMRA) were gen-
erated using sortase A as described earlier (44). Hybridoma cells secreting
mouse monoclonal anti-IAV NP (clone H16-L10-4R5; ATCC HB-65)
were obtained from ATCC, and antibodies in the supernatant were puri-
fied using a protein G column.
Infection assay. To analyze the effect of NP-VHH1 expressed at dif-
ferent times during infection, A549 cells inducibly expressing the VHH
were infected with A/WSN/33 at a multiplicity of infection (MOI) of 1.
VHH expression was induced at the indicated time points relative to in-
fection with 1 g/ml doxycycline (final concentration). Six hours postin-
fection, cells were trypsinized, fixed in 4% paraformaldehyde (PFA), per-
meabilized with 0.1% saponin, and stained with anti-HA-AF488 and
NP-VHH2-AF647. Fraction of infected cells (NP) and geometric mean
fluorescence intensity (VHH-HA) were quantified by flow cytometry us-
ing a BD Accuri cytometer and the FlowJo software package.
Titration of released virus. To quantify release of progeny virus from
cells expressing NP-VHH1, A549 cells inducibly expressing the VHH
were infected with A/WSN/33 at an MOI of 1 in the presence of tosylsul-
fonyl phenylalanyl chloromethyl ketone (TPCK) trypsin. VHH expres-
sion was induced at the indicated time points relative to infection with
1 g/ml doxycycline (final concentration). Twenty-four hours postinfec-
tion, supernatants were collected, filtered, diluted in a 2-fold dilution
series, and used to infect MDCK cells for 1 h at 37°C. The inoculum was
replaced with DMEM, 0.35% BSA, and 1.5% carboxymethyl cellulose in
the absence of trypsin to avoid spreading of the virus. After 24 h, cells were
fixed in 4%PFA, permeabilizedwith 0.1% saponin in phosphate-buffered
saline (PBS)–2% BSA, and stained with 4=,6-diamidino-2-phenylindole
(DAPI) and NP-VHH2-TAMRA. Fluorescence images of the MDCK
monolayer were acquired using a Cytation 3 cell imaging multimode
reader (BioTek); infected cells (nuclei) were quantified using CellProfiler
(45).
Influenza virus polymerase reconstitution assay.To assess influenza
virus polymerase activity, 293T cells were transiently transfected with
200 ng of pCAGGS NP and 50 ng of pCAGGS PB1, pCAGGS PB2, and
pCAGGS PA. To provide an artificial genome segment, 50 ng of pPolI-RT
plasmid was cotransfected, from which an artificial genome segment was
transcribed that contained the NA untranslated regions and encoded ei-
ther EGFP or mCherry-2TA-EGFP. One hundred fifty nanograms of
pCAGGS vector encodingNP-VHH1, VHH7 (anti-murine-MHCII), or
pCDNA3.1 encoding MxA or Mx1 was additionally cotransfected where
indicated. All transfections were performed using Lipofectamine 2000.
Twenty-four hours posttransfection, cells were trypsinized and the frac-
tion of EGFP-positive cells was quantified by flow cytometry using a BD
Accuri cytometer.
Protein expression and purification. The sequence encoding NP-
VHH1with a C-terminal sortase recognition site (LPETG) followed by
a His tag was cloned into a pHEN6 expression vector for periplasmic
expression. Escherichia coli WK6 bacteria were transformed with the
vector, and expression was induced with 1 mM isopropyl--D-
thiogalactopyranoside (IPTG) at an optical density at 600 nm (OD600)
of 0.6; cells were grown overnight at 30°C. The VHH was retrieved
from the periplasm by osmotic shock and purified by Ni-NTA affinity
purification and size exclusion chromatography on a Superdex 75 col-
umn.
NP from influenza virus A/WSN/33 with a C-terminal His tag was
cloned into the pET30 expression vector. E. coli BL21(DE3) bacteria were
transformed and grown in Terrific Broth at 37°C until reaching an OD600
of 0.5 and at 25°C until reaching an OD600 of 0.6. Protein expression was
induced with 1 mM IPTG at an OD600 of 0.6, and cells were grown for an
additional 3 h at 25°C. Bacterial pellets were resuspended in 25 mM Tris-
HCl, pH 7.5, 1 M NaCl, 0.2% NP-40, 10 units/ml Benzonase, and
0.1 mg/ml lysozyme. Cells were lysed by sonication, and NP was purified
on Ni-NTA agarose, Mono S ion exchange, and Superdex 200 size exclu-
sion columns.
Crystallization. For cocrystallization, purified NP-VHH1 was
mixed in a 3:1 molar ratio with recombinant NP and purified by size
exclusion on a Superdex 200 column. Both tri- and monomeric peaks
were collected, and VHHbinding was confirmed by SDS-PAGE and Coo-
massie blue staining. The complexwas concentrated to 4mg/ml in 20mM
Tris-HCl, pH 7.5, 200 mM NaCl buffer using a protein concentrator.
Initial crystal growth was observed in 0.1M sodium acetate-1.5M ammo-
nium sulfate in a vapor diffusion experiment in a 96-well sitting drop
setup (Procomplex; Qiagen) at 18°C. Crystal growth was optimized with
0.025% (vol/vol) dichloromethane, and diffraction-quality crystals were
grown in a 24-well vapor diffusion hanging drop setup. Crystals were
cryoprotected in 20% glycerol and flash frozen in liquid nitrogen.
Data processing and structure determination. Data sets were col-
lected at the Advanced Photon Source user end station 24-IDC. Data
reductionwas performed inHKL2000 (46).Molecular replacement (MR)
was performed in the PHENIX suite using PhaserMR (47). As an MR
model for NP, we used PDB identifier (ID) 2IQH (NP) (1) and PDB ID
4KRL (VHH) (21). Refinement was performed using phenix.refine, and
the model was built in Coot (48).
Purificationof vRNPs and electronmicroscopy. vRNPswere isolated
and purified from IAV PR8 virions as described elsewhere (49). In brief,
influenza virus A/PR/8/34 was concentrated and virions were lysed in
100 mMKCl, 5 mMMgCl2, 5% (wt/vol) glycerol, 50 mM octylglucoside,
10 mg/ml lysolecithin, 1.5 mM dithiothreitol, 100 mM morpho-
lineethanesulfonic acid (MES), pH 5.5. vRNPs were then separated from
other viral proteins on a glycerol gradient and concentrated. vRNPs were
treated with an excess of NP-VHH1 or the control VHH in 50 mM
Tris-HCl, pH 7.5, 150mMNaCl and subsequently stainedwith 2%uranyl
acetate. Electronmicrographs were recorded with a FEI Tecnai Spirit Bio-
Twin microscope, and images were analyzed with ImageJ.
LUMIER assay.To analyze binding of VHHs to wild-type andmutant
versions of IAV NP, we applied LUMIER assays as described in detail
before (17). 293T cells were cotransfected with pCAGGS anti-NP-
VHH1-HA and wild-type or mutant E375R pEXPR NP-Renilla (derived
from NP of influenza virus A/WSN/33) or pEXPR VSV-N-Renilla using
Lipofectamine 2000. Twenty-four hours posttransfection, cells were lysed
and incubated in Lumitrac 600 96-well plates (Greiner) coated with anti-
HA.11 antibody to capture the VHH. Activity of the copurified luciferase
was quantified by addition of coelenterazine-containingRenilla luciferase
substrate mix (BioLux Gaussia luciferase assay kit; New England Bio-
Labs), and light emission was measured using a SpectraMax M3 micro-
plate reader (Molecular Devices).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org/
lookup/suppl/doi:10.1128/mBio.01569-16/-/DCSupplemental.
Figure S1, TIF file, 0.8 MB.
Figure S2, TIF file, 0.2 MB.
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